Companies in #Large B-Cell Lymphoma
Found 1 company operating in this sector.
Allogene Therapeutics (NASDAQ: ALLO) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. Allogene's lead clinical programs include cemacabtagene ansegedleucel (cema-cel, ALLO-501A) for relapsed/refractory large B-cell lymphoma and the ALPHA3 trial of ALLO-329 (a CD19/CD70 dual-allogeneic CAR T) in autoimmune disease. The company was founded in 2017 by acquiring Pfizer's allogeneic CAR-T portfolio and is led by CEO Dr. Zach Roberts as of June 30, 2026.